Contact
 

Timely Topics in HIV Vaccines

The search for a safe and effective HIV vaccine has progressed further and faster in the last few years than at any time since the epidemic began. This progress poses new questions, new opportunities and new challenges as to what and how the HIV vaccine research endeavor should move forward.

298

In 2012, the Enterprise launched Timely Topics in HIV Vaccines, a strategy series convening experts as rapidly as possible to analyze, address, and respond to unresolved and emerging priority issues in the field. Through an open call for proposals, the Enterprise is working to identify the most important strategic needs of the field and sponsoring think tanks, meetings, forums and other events to tackle these issues.

We will carefully review all ideas, and are particularly interested in topics that:

  • help keep the field broad, open, and cutting edge, which includes building on lessons from early HIV infection and pathogenesis, other HIV prevention research, new technologies, or vaccines against other diseases;
  • by defining protective mechanisms in a variety of models, help refine criteria for vaccine design and optimization, in hopes of informing decision-making and improving the chances of success in efficacy trials;
  • lead to better incorporation and emphasis on development pathways, enabling better selection of candidates, more effective longer-term planning and preparation, and smoother transition between development phases.

Tell us what priority issues/opportunities you believe will facilitate HIV vaccine research and development. Individuals, groups and organizations are invited to submit ideas/topics at any time, submitted ideas will be reviewed on a rolling basis. If selected, we will work with you to develop and implement a plan to convene and address the proposed issue/opportunity and will provide full or partial support for the convening depending on the opportunity.

Learn more about the process to submit and evaluate topics here. 

 

2013 Timely Topics

HIV Prevention Trials in Infants
January Consultation

Vaccine-Induced Sero-Positivity (VISP) 
March Consultation

Bench to Clinic Tool
Now Available! Web-based tool to guide in taking candidates from concept to Phase I trials

Datasharing
Strengthening policies to broaden access to HIV vaccine research

Capturing Participants Information for Mucosal Sampling: An Investigator's Guide
Coming Soon! Guide to help capture participant parameters that impact mucosal responses

Therapeutic Vaccines
A consultation to help determine the intersection between therapeutic and preventive vaccines 

Antibody Durability
Think tank on inducing durable antibody responses through HIV vaccination 

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account